Encompass Health insider plans sale of 2,804 shares

Encompass Health Corporation has a shareholder filing a notice to sell 2,804 shares of its common stock under Rule 144.

Rhea-AI Filing Summary

Encompass Health Corporation has a shareholder filing a notice to sell 2,804 shares of its common stock under Rule 144. The planned sale through UBS Financial Services Inc. is listed with an aggregate market value of 301755, with trading on the NYSE around 02/10/2026.

The shares to be sold were acquired from Encompass Health Corporation through restricted stock unit vesting on 02/23/2024 and 02/24/2024, and performance stock unit vesting on 01/01/2025. Shares outstanding were 100,615,977 common shares at the time referenced.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Encompass Health (EHC) disclose?

The filing discloses a shareholder’s intent to sell 2,804 Encompass Health common shares under Rule 144. The sale is planned through UBS Financial Services Inc. on the NYSE, with an aggregate market value reported as 301755 and 100,615,977 shares outstanding.

How many Encompass Health (EHC) shares are planned to be sold and where?

The notice covers the planned sale of 2,804 Encompass Health common shares. The transaction is listed to occur through UBS Financial Services Inc., naming the NYSE as the securities exchange where the shares are expected to trade around 02/10/2026.

How were the Encompass Health (EHC) shares in this Form 144 acquired?

The shares were acquired from Encompass Health Corporation through equity awards. Restricted stock units vested on 02/23/2024 and 02/24/2024, while performance stock units vested on 01/01/2025, resulting in multiple blocks of common stock later scheduled for payment on 02/10/2026.

What is the aggregate market value of Encompass Health (EHC) shares in this planned sale?

The filing lists an aggregate market value of 301755 for the 2,804 Encompass Health common shares to be sold. This figure reflects the market value at the time of the filing’s preparation for the proposed Rule 144 transaction through UBS Financial Services Inc.

How many Encompass Health (EHC) shares were outstanding in this Form 144 notice?

The filing reports 100,615,977 Encompass Health common shares outstanding. This number provides context for the Rule 144 sale involving 2,804 shares, indicating the broader share base of the issuer at the time referenced in the notice.

Which broker is handling the Encompass Health (EHC) Rule 144 sale?

The planned sale is listed with UBS Financial Services Inc. as broker, located at 1000 Harbor Blvd, 3rd Floor, Weehawken, NJ 07086. The NYSE is named as the securities exchange where the 2,804 Encompass Health common shares are expected to be sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 02:24 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002065822
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Encompass Health Corporation
SEC File Number	001-10315
Address of Issuer	9001 Liberty Parkway Birmingham ALABAMA 35242
Phone	205-967-7116
Name of Person for Whose Account the Securities are To Be Sold	Patrick Tuer
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	2804	301755	100615977	02/10/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/23/2024	RSU Vesting	Encompass Health Corporation			408	02/10/2026	N/A
Common Stock	02/24/2024	RSU Vesting	Encompass Health Corporation			238	02/10/2026	N/A
Common Stock	01/01/2025	PSU Vesting	Encompass Health Corporation			200	02/10/2026	N/A
Common Stock	01/01/2025	PSU Vesting	Encompass Health Corporation			1958	02/10/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/10/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/JOSEPH CASSIDY, for UBS Financial Services Inc, as attorney-in-fact for Patrick Tuer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)